tirzepatide osa trial VisualAbstract: Improved Outcomes in Patients with Obstructive Sleep Apnea and Obesity Tirzepatide and Semaglutide: Impact on

50,53,54 The limitation of this review is that we only searched two databases, so it is possible that we missed one study, which may reduce the validity and subsequent reliability of the findings

Colleen McCabe, PharmD, BCOP, and Lindsay Mundy, PharmD, BCOP, led an engaging exploration of the benefits and potential pitfalls with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in an oncology setting in their presentation, GLP-1s in Oncology: Miracle, Misdirection, or Missed Opportunity

SURMOUNT-2, in participants with type 2 diabetes, showed 12.8% and 14.7% weight loss at 10mg and 15mg respectively

This apparent between-group difference was driven primarily by a decreased incidence of stroke and coincided with greater reductions in weight and glycated hemoglobin